Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma reported financial results for 2020, revealing a revenue decline of 17.9% to €70.5 million, attributed mainly to a drop in collaboration income from AstraZeneca. The company faced a net loss of €64 million, up from €20.8 million the previous year, partly due to a €43.5 million impairment on Lumoxiti assets after returning commercialization rights to AstraZeneca. Despite challenges, Innate achieved significant milestones, including PRIME designation for lacutamab and a Phase 3 trial startup for monalizumab, contributing to a cash position of €190.6 million by year-end.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) will hold a conference call on March 18, 2021, at 2 p.m. CET / 9 a.m. ET to discuss its financial results for the year ending December 31, 2020. Key executives, including CEO Mondher Mahjoubi and CFO Laure-Hélène Mercier, will provide insights during the call. Participants can join the call via a live webcast or telephone registration, with a replay available for 90 days. Innate Pharma is focused on oncology and has partnerships with major biopharmaceutical firms, emphasizing its commitment to innovative cancer treatments.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its total number of shares outstanding as of February 1, 2021. The company has 78,989,740 ordinary shares, including 6,856 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights is 79,799,621, while the exercisable voting rights stand at 79,781,046. This disclosure complies with French regulation and emphasizes Innate Pharma's commitment to keeping investors informed regarding shareholding positions and governance.
Innate Pharma SA (Euronext: IPH, Nasdaq: IPHA) announced that its senior management will participate in the 10th Annual SVB Leerink Global Healthcare Conference from February 24-26, 2021. A fireside chat is scheduled on February 24 from 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ET. The event will be available via live webcast on the company's website, with a replay accessible for 90 days post-event. Innate Pharma focuses on oncology and uses therapeutic antibodies to enhance cancer treatment, collaborating with major biopharmaceutical companies.
Innate Pharma SA (Nasdaq: IPHA) announced significant progress in clinical development for lacutamab, an anti-KIR3DL2 antibody targeting T-cell lymphomas. The KIR3DL2-expressing mycosis fungoides cohort in the TELLOMAK trial has advanced to Stage 2 ahead of schedule, with preliminary positive results prompting further recruitment. Additionally, two new trials will investigate lacutamab's efficacy in peripheral T-cell lymphoma, including a Phase 2 study in collaboration with LYSA. These developments suggest a strategic push into earlier lines of therapy and enhancement of treatment options for patients.
Innate Pharma will host a virtual key opinion leader (KOL) discussion on February 9, 2021, at 2:00 p.m. CET / 8:00 a.m. ET, focusing on its investigational drug lacutamab for T-cell lymphomas. Presentations will be made by notable KOLs, including Pierluigi Porcu and Olivier Hermine, highlighting the drug's impact and clinical trials. The event is accessible via webcast, with registration required for dial-in details. Lacutamab targets KIR3DL2, present in a significant percentage of patients with cutaneous T-cell lymphoma, a challenging orphan disease.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced the progression of IPH6101/SAR443579, an NKp46-based NK cell engager, into IND-enabling studies by Sanofi. This decision triggers a €7M milestone payment to Innate. The drug candidate has shown promising anti-tumor activity in pre-clinical models, including positive pharmacokinetic and safety data. Sanofi will lead future development and commercialization. This milestone is part of a collaboration allowing Innate to earn up to €400M in future development and commercial milestones.
Innate Pharma announced that Sanofi will advance the NKp46-based NK cell engager, IPH6101/SAR443579, into IND-enabling studies. This decision triggers a €7M milestone payment to Innate. The drug candidate has shown anti-tumor activity and promising safety data in non-human primate studies. Sanofi will handle ongoing development and commercialization. The collaboration could yield up to €400M in milestone payments and royalties for Innate. This development marks a significant step in the application of Innate’s proprietary multi-specific antibody technology in cancer therapy.
Innate Pharma announced its participation in two upcoming virtual investor conferences. The ODDO BHF Digital Forum will take place from January 7-11, 2021, and the SternIR Virtual Corporate Access Event from January 11-14, 2021. A pre-recorded presentation will be accessible on-demand starting January 11, 2021, on their website. Innate Pharma focuses on oncology and aims to enhance treatment outcomes through innovative therapeutic antibodies. The company is recognized for its alliances with major biopharmaceutical leaders and has a robust pipeline of clinical candidates.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced it will return US and EU commercialization rights of Lumoxiti to AstraZeneca due to low product sales and strategic reassessment. The transition plan includes costs and transfer logistics, with the goal of completing the handover by 2021. The company will maintain patient and customer support during the transition but will cease regulatory activities in the EU. As of June 30, 2020, Lumoxiti's net book value stood at €45.2 million. Innate aims to refocus investments on its R&D portfolio for future growth.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
